The latest from Faes Farma


June 25th, 2026

Faes Farma holds its Annual General Shareholders’ Meeting following a key year in the execution of its Strategic Plan


Shareholders approved all items on the agenda, including the 2025 annual accounts, as well as the appointment of Jacobo Llanza and Ángel Agudo as members of the Board of Directors. The Meeting […]



More info

April 30th, 2026

Faes Farma exceeds €200 million in revenue (+31%) and increases its net profit by +9% in the first quarter


Revenue grew by +31%, exceeding guidance, driven by the strength of international markets, both in direct sales and licensing, alongside acquisitions. The Pharma business reached €175 million (+31%), with ophthalmology establishing itself […]



More info

February 26th, 2026

Faes Farma increases its revenue by 23% to €627 million


Strong performance across all business areas enabled the company to close the 2025 financial year with organic revenue above guidance and adjusted EBITDA in line with expectations. The Pharma division achieved double-digit […]



More info

All the news